<DOC>
	<DOCNO>NCT00261378</DOCNO>
	<brief_summary>The objective study assess safety efficacy DC Bead™ deliver intra-arterial embolisation treatment Hepatocellular Carcinoma</brief_summary>
	<brief_title>Prospective Randomised Study Doxorubicin Treatment Hepatocellular Carcinoma Drug-Eluting Bead Embolisation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Inclusion criterion Patients confirm diagnosis HCC accord EASL criterion diagnosis , see appendix 4 stag accord BCLC criterion . Patient choose participate sign informed consent document Age 18 year old Patients HCC suitable resection percutaneous ablation accord BCLC Staging classification , see Figure 2 . Patient eligible resection percutaneous ablation treatment unfeasible patient decline . This decision must document patient 's record . Patient eligible chemoembolisation prior transplantation expect transplant wait time exceed 6 month . Patients demonstrate recurrence follow potentially curative treatment ( resection percutaneous ablation ) clearly measurable disease accord RECIST EASL Patients Performance Status ECOG 0 1 Patients well preserve liver function ( ChildPugh A B ) Patients bilobar disease treat superselectively single session lobes able treat within 3 week . Exclusion criterion Patients another primary tumour , exception conventional basal cell carcinoma superficial bladder neoplasia Patients previously treat transarterial embolisation ( without chemotherapy ) . Patients previously treat anthracyclines ( ie doxorubicin ) . Patients ' whose measurable disease within area liver previously subject radiotherapy . Advanced liver disease : ChildPugh C , active gastrointestinal bleeding , encephalopathy clinically relevant ascites . Bilirubin level &gt; 3mg/dl Advanced tumoural disease : BCLC class C , ( vascular invasion include segmental portal obstruction , extrahepatic spread cancerrelated symptoms= ECOG 2 , 3 4 ) BCLC class D ( WHO performance status 3 4 , Okuda III stage ) Diffuse HCC define &gt; 50 % tumour involvement whole liver Any contraindication doxorubicin administration : serum bilirubin &gt; 5mg/dL , WBC &lt; 3000 cells/mm3 neutrophil &lt; 1500 cells/mm3 , cardiac ejection fraction &lt; 50 percent assess isotopic ventriculography , echocardiography MRI Any contraindication hepatic embolisation procedure : portosystemic shunt , hepatofugal blood flow ; impaired clotting test ( platelet count &lt; 50000/mm3 , prothrombin activity &lt; 50 percent ) , renal insufficiency/failure , serum creatinine &gt; 2mg/dl ( 177umol/l ) severe atheromatosis , AST and/or ALT &gt; 5x ULN , great &gt; 250U/l Women pregnant breast feeding Allergy contrast medium Contraindication hepatic artery catheterisation , severe peripheral vascular disease preclude catheterisation The availability alternative therapy , judgment physician ( refer treat ) , appropriate patient Any comorbid disease condition event , investigator 's judgment , would place patient undue risk , would preclude safe use DC Bead™ , TACE Patients contraindicate MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Hepatocellular Carcinoma ( HCC )</keyword>
</DOC>